Ensign Peak Advisors
BBIO icon

Ensign Peak Advisors’s BridgeBio Pharma BBIO Stock Holding History

Ensign Peak Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.7M Sell
760,977
-75,575
-9% -$5.29M 0.09% 181
2026
Q1 		$62.1M Sell
836,552
-426,932
-34% -$30.9M 0.12% 158
2025
Q4 		$96.6M Sell
1,263,484
-88,095
-7% -$5.78M 0.17% 116
2025
Q3 		$70.2M Buy
1,351,579
+35,600
+3% +$1.74M 0.12% 157
2025
Q2 		$56.8M Sell
1,315,979
-534,060
-29% -$19.4M 0.1% 184
2025
Q1 		$64M Sell
1,850,039
-125,210
-6% -$4.22M 0.12% 162
2024
Q4 		$54.2M Buy
1,975,249
+89,495
+5% +$2.31M 0.1% 181
2024
Q3 		$48M Buy
1,885,754
+239,552
+15% +$6.29M 0.08% 192
2024
Q2 		$41.7M Buy
1,646,202
+506,845
+44% +$13.9M 0.08% 201
2024
Q1 		$35.2M Buy
1,139,357
+394,286
+53% +$13.4M 0.06% 227
2023
Q4 		$30.1M Buy
745,071
+112,361
+18% +$3.37M 0.06% 254
2023
Q3 		$16.7M Sell
632,710
-447,549
-41% -$12.7M 0.04% 296
2023
Q2 		$18.6M Hold
1,080,259
– – 0.04% 309
2023
Q1 		$17.9M Buy
1,080,259
+256,300
+31% +$2.99M 0.04% 297
2022
Q4 		$6.28M Buy
823,959
+262,461
+47% +$2.51M 0.01% 507
2022
Q3 		$5.58M Buy
561,498
+71,786
+15% +$746K 0.01% 500
2022
Q2 		$4.45M Buy
489,712
+24,629
+5% +$206K 0.01% 568
2022
Q1 		$4.72M Sell
465,083
-7,186
-2% -$73.7K 0.01% 613
2021
Q4 		$7.88M Sell
472,269
-2,551
-0.5% -$108K 0.02% 525
2021
Q3 		$22.3M Buy
474,820
+90,682
+24% +$4.86M 0.05% 300
2021
Q2 		$23.4M Buy
384,138
+28,815
+8% +$1.65M 0.05% 293
2021
Q1 		$21.9M Buy
355,323
+175,617
+98% +$11.5M 0.05% 297
2020
Q4 		$12.8M Sell
179,706
-26,945
-13% -$1.3M 0.03% 383
2020
Q3 		$7.75M Buy
206,651
+57,568
+39% +$1.81M 0.02% 501
2020
Q2 		$4.86M Buy
149,083
+6,848
+5% +$209K 0.01% 614
2020
Q1 		$4.13M Buy
142,235
+31,810
+29% +$986K 0.01% 562
2019
Q4 		$3.87M Buy
+110,425
New +$3.06M 0.01% 724

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ensign Peak Advisors's BBIO Position: Q2 2026 in Review

Ensign Peak Advisors reduced its BridgeBio Pharma (BBIO) stake by 9% in Q2 2026, selling an estimated $5.29M and leaving 760,977 shares worth $56.7M. The position accounts for 0.09% of the portfolio, ranked #181.

Ensign Peak Advisors first reported a position in BBIO in Q4 2019 and has held it in 27 quarters since. The position peaked at $96.6M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Ensign Peak Advisors held 760,977 shares of BridgeBio Pharma worth $56.7M as of Q2 2026.
  • Ensign Peak Advisors sold 75,575 BridgeBio Pharma shares in Q2 2026, an estimated $5.29M.
  • BridgeBio Pharma made up 0.09% of Ensign Peak Advisors's portfolio in Q2 2026, its #181 holding.
  • Ensign Peak Advisors first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's BridgeBio Pharma position peaked at $96.6M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.